>>**Entry Name: Ranitidine,** BAN, INN, JAN, USAN
Synonym(s): *N*-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-*N*'-methyl-2-nitro-1,1-ethenediamine, 9CI



CAS Registry Number: 66357-35-5

Molecular Formula: $C_{13}H_{22}N_4O_3S$
Molecular Weight: 314.408
Accurate Mass: 314.141261
Percentage Composition: C 49.66%; H 7.05%; N 17.82%; O 15.27%; S 10.20%
Biological Use/Importance: Histamine H_2-receptor antagonist. Antiulcer agent, low toxicity
Development Status: Marketed drug. Worldwide 50th best selling prescription drug (as Zantac) ($0.87 bn) (GlaxoSmithKline) (2000, Pharma Business)
Melting Point: Mp 69-70°
Calculated Log P Data: Log P 1.33 (uncertain value) (calc)

Sigma: R0633

>>**Derivative:** Hydrochloride
Synonym(s): Ranitidine hydrochloride, JAN, USAN**.** Azantac. Melfax. **Noctone‡.** Ranaps. Raniben. Ranidil. Raniplex. Rantec. Sostril. Taural. Terposen. Trigger. Ultidine. Zaedoc. Zantac. Zantidon. AH 19065. Many other names

CAS Registry Number: 71130-06-8
Extra CAS Registry Numbers(s): 66357-59-3
Melting Point: Mp 133-134°

>>**Derivative:** Compd. with bismuth citrate (1:1)
Synonym(s): Ranitidine bismuth citrate, BAN, USAN**.** Ranitidine bismutrex. Elicodil. Helirad. Pylorid. Pylorisin. Tritec. GR 122311X

CAS Registry Number: 128345-62-0
Molecular Formula: $C_{19}H_{27}BiN_4O_{10}S$
Molecular Weight: 712.489
Accurate Mass: 712.125165
Percentage Composition: C 32.03%; H 3.82%; Bi 29.33%; N 7.86%; O 22.46%; S 4.50%
Biological Use/Importance: Used in the eradication of *Helicobacter pylori*
Physical Description: No phys. props. reported
Development Status: Launched 1995

References:

Ger. Pat., 1978, *Allen and Hanburys*, 2 734 070; *CA*, **88**, 190580b, *(synth, pharmacol)*
Daly, M.J. *et al.*, *Br. J. Pharmacol.*, 1981, **72**, 49; 55, *(pharmacol)*
Kojic-Prodic, B. *et al.*, *Acta Cryst. B*, 1982, **38**, 1837, *(cryst struct)*
Riley, A.J. *et al.*, *Curr. Clin. Pract. Ser.*, (Eds.), No. 1: *Ranitidine*, Excerpta Medica, Amsterdam, 1982, *(book)*
Brogden, R.N. *et al.*, *Drugs*, 1982, **24**, 267, *(rev, pharmacol)*
Gaginella, T.S. *et al.*, *Drug Intell. Clin. Pharm.*, 1983, **17**, 873, *(rev, pharmacol)*
Daly, M.J. *et al.*, *Prog. Med. Chem.*, 1983, **20**, 337, *(rev, pharmacol)*
Misiewicz, J.J. *et al.*, *Curr. Clin. Pract. Ser.*, 1984, **15**, *(book)*
Cholerton, T.J. *et al.*, *J.C.S. Perkin 2*, 1984, 1761, *(uv, ir, pmr, struct)*
Hohnjec, M. *et al.*, *Anal. Profiles Drug Subst.*, 1986, **15**, 533, *(rev, synth, anal, metab)*
Geraldes, C.F. *et al.*, *Magn. Reson. Chem.*, 1987, **25**, 203, *(pmr, cmr)*
Negwer, M.*, Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag*, 1987, 2946
Kirch, W.*, Pharmacol. Ther.*, 1987, **33**, 129, *(rev)*
Grant, S.M. *et al.*, *Drugs*, 1989, **37**, 801, *(pharmacol, rev)*
Spurling, N.W. *et al.*, *Hum. Toxicol.*, 1989, **8**, 23, *(chronic tox)*
The Landmark Papers: The H2-Receptor Antagonists, (Ed. Pounder, R.E.), Science Press, 1990, *(pharmacol, book)*
U.K. Pat., 1990, *Glaxo*, 2 220 937; *CA*, **113**, 65266n, *(Ranitidine bismutrex)*
Stables, R. *et al.*, *Aliment. Pharmacol. Ther.*, 1993, **7**, 237, *(Ranitidine bismutrex, pharmacol)*
Bradshaw, J.*, Chron. Drug Discovery*, 1993, **3**, 45, *(rev)*
Wormsley, K.G.*, Drugs*, 1993, **46**, 976, *(tox, rev)*
Bardhan, K.D. *et al.*, *Aliment. Pharmacol. Ther.*, 1995, **9**, 497, *(Ranitidine bismutrex)*
Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 1209; 1211
Lewis, R.J.*, Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold*, 1992, RBF400